Torge Rempe

A Randomized, Phase 3, Open-Label Study to investigate Pharmacokinetics, Safety and Efficacy of subcutaneous compared to intravenous Frexalimab in Adult Participants with Multiple Sclerosis

A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Real-world experience with BRIUMVI® (ublituximab-xiiy) treated patients: a longitudinal registry study (ENABLE)

An Interventional, Phase 3 Extension Study to Investigate Long-Term Safety and Tolerability of Tolebrutinib in Participants with Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis or Nonrelapsing Secondary Progressive Multiple Sclerosis

An open-label, randomized, parallel group, non-inferiority study to investigate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new maintenance dosing regimen of ofatumumab, followed by extended treatment in participants with relapsing multiple sclerosis”

Efficacy and safety of remibrutinib and participant satisfaction after switching from ocrelizumab in people living with relapsing multiple sclerosis

A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants with Nonrelapsing Secondary Progressive Multiple Sclerosis”

CTOA Rempe

A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib

AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Naïve, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes

A Phase III, Randomized, Double Blind, Placebo controlled, Multi center Study To Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab as Monotherapy or in Addition to Baseline Therapy in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)

A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio) in participants with relapsing forms of multiple sclerosis (GEMINI 2)

A PHASE 3B, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE IMMUNE RESPONSE TO, AND THE SAFETY OF, VACCINES IN PARTICIPANTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHO RECEIVE ORAL OZANIMOD COMPARED TO NON-PEGYLATED INTERFERON-B OR NO DISEASE MODIFYING THERAPY

TRADITIONAL VERSUS EARLY AGGRESSIVE THERAPY FOR MULTIPLE SCLEROSIS (TREAT-MS) TRIAL

A pragmatic trial to evaluate the intermediate-term effects of early, aggressive versus escalation therapy in people with multiple sclerosis

CMSC has created the North American Registry for Care and Research in Multiple Sclerosis